Evidence map›Paper›PMID 30170085›Full record

ArticleNeuropharmacology2018

Nicotine modulates contextual fear extinction through changes in ventral hippocampal GABAergic function.

Munir Gunes Kutlu, David A Connor, Jessica M Tumolo, Courtney Cann, Brendan Garrett, Thomas J Gould

Open access · greenAbstract read
In one paragraph

Article in Neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Munir Gunes KutluThe Department of Biobehavioral Health, Pennsylvania State University, University Park, PA, USA. Electronic address: gunes.kutlu@vanderbilt.edu.
David A ConnorDepartment of Neuroscience, Perelman School of Medicine, University of Pennsylvania Medical School, Philadelphia, PA, USA.
Jessica M TumoloDepartment of Psychology, Temple University, Philadelphia, PA, USA.
Courtney CannThe Department of Biobehavioral Health, Pennsylvania State University, University Park, PA, USA.
Brendan GarrettDepartment of Psychology, Temple University, Philadelphia, PA, USA.
Thomas J GouldThe Department of Biobehavioral Health, Pennsylvania State University, University Park, PA, USA.
Pennsylvania State University · USTemple University · USUniversity of Pennsylvania · US

Funding

Nicotine Addiction: Learning, Neural &Genetic ProcessR01DA017949 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI GOULD, THOMAS J · 2005 to 2015
$2.7M
Gene Variants for Nicotine Withdrawal Deficits in LearningU01DA041632 · NIDA · PENNSYLVANIA STATE UNIVERSITY, THE · PI GOULD, THOMAS J · 2016 to 2020
$1.8M
NIDA NIH HHS R01 DA017949NIDA NIH HHS U01 DA041632
6 · The paper itself

Abstract

Numerous studies have attributed the psychopathology of anxiety and stress disorders to maladaptive behavioral responses such as an inability to extinguish fear. Therefore, understanding neural substrates of fear extinction is imperative for developing more effective therapies for anxiety and stress disorders. Although several studies indicated a role for cholinergic transmission and nicotinic acetylcholine receptors (nAChRs) in anxiety and stress disorder symptomatology, very little is known about the specific contribution of nAChRs in the fear extinction process. In the present study, we first examined the involvement of several brain regions essential for fear extinction (i.e., dorsal and ventral hippocampus, dHPC and vHPC; infralimbic, IL, and prelimbic, PL of the medial prefrontal cortex, mPFC; basolateral nucleus of the amygdala, BLA) in the impairing effects of a nAChR agonist, nicotine, on contextual fear extinction in mice. Our results showed that systemic administration of nicotine during contextual fear extinction increased c-fos expression in the vHPC and BLA while not affecting dHPC, IL or PL. In line with these results, local nicotine infusions into the vHPC, but not dHPC, resulted in impaired contextual fear extinction. Interestingly, we found that local nicotine infusions into the PL also resulted in impairment of contextual fear extinction. Second, we measured the protein levels of the GABA synthesizing enzymes GAD65 and GAD67 in the dHPC and vHPC during contextual fear extinction. Our results showed that in the group that received acute nicotine, both GAD65 and GAD67 protein levels were downregulated in the vHPC, but not in dHPC. This effect was negatively correlated with the level of freezing response during fear extinction suggesting that the downregulated GAD65/67 levels were associated with disrupted fear extinction. Finally, using c-fos/GAD65/67 double immunofluorescence, we showed that nicotine mainly increased c-fos expression in non-GABAergic ventral hippocampal cells, indicating that acute nicotine increases vHPC excitability. Overall, our results suggest that acute nicotine's impairing effects on fear extinction are associated with ventral hippocampal disinhibition. Therefore, these results further our understanding of the interaction between nicotine addiction and anxiety and stress disorders by describing novel neural mechanisms mediating fear extinction.

Indexed as

AmygdalaAnimalsDown-RegulationExtinction, PsychologicalFearGlutamate DecarboxylaseHippocampusImmobility Response, TonicMaleMiceMicroinjectionsNicotinePrefrontal CortexProto-Oncogene Proteins c-fosGlutamate Decarboxylaseglutamate decarboxylase 1glutamate decarboxylase 2NicotineProto-Oncogene Proteins c-fosFear extinctionGABAHippocampusNicotinic receptorsPTSD

Identifiers

PMID30170085
PMCPMC6170695
OpenAlexW2888900943

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.